Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
PaperCitations, authors & open-access status
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 808 citations, 2018 year and green oa status.
808
Citations
2018
Year
green
OA Status